#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to recognize that CBD has FDA-approved evidence for treating certain seizure disorders, particularly Dravet syndrome and Lennox-Gastaut syndrome, offering patients a therapeutic option when conventional antiepileptic drugs fail or cause unacceptable side effects. Understanding cannabis medicine’s role in epilepsy management enables clinicians to have informed discussions with patients about risks, benefits, and drug interactions, improving treatment outcomes and adherence. This knowledge gap directly affects patient care quality, as many clinicians lack training on cannabinoid pharmacology despite its established clinical utility in refractory epilepsy.
Cannabidiol (CBD), a non-intoxicating cannabinoid derived from cannabis, represents an important therapeutic option for epilepsy management, particularly for patients with treatment-resistant seizure disorders who have exhausted conventional antiepileptic drug options. Unlike tetrahydrocannabinol (THC), CBD does not produce intoxicating effects, making it suitable for patients seeking seizure control without cognitive impairment or abuse potential. The inclusion of CBD in epilepsy treatment regimens addresses a significant clinical gap, as many patients with certain epilepsy types (such as Dravet syndrome and Lennox-Gastaut syndrome) demonstrate inadequate response to standard medications. Clinicians should be aware that FDA-approved CBD products like Epidiolex now provide a regulated, evidence-based alternative that can be incorporated into comprehensive seizure management protocols. For patients with refractory epilepsy, discussing CBD as a potential adjunctive or alternative therapy may improve outcomes and quality of life when conventional approaches have proven insufficient.
“We do have FDA-approved CBD formulations like Epidiolex with solid evidence for specific seizure disorders, particularly Dravet and Lennox-Gastaut syndromes, so for those particular patient populations the clinical case is genuinely there. That said, the broader landscape of cannabis and cannabinoids in epilepsy care remains incomplete, and I’m careful to distinguish between what’s proven in controlled trials versus the anecdotal reports we see circulating, because parents understandably want answers but we owe them honest assessment of what we actually know.”
💊 Cannabidiol represents a meaningful addition to the epilepsy treatment armamentarium, particularly for patients with treatment-resistant seizure disorders who have exhausted conventional antiepileptic options. The distinction between CBD and THC is clinically important, as CBD’s non-intoxicating profile addresses safety concerns that previously limited cannabis-based therapies in vulnerable populations like children. However, clinicians should remain cautious about several practical challenges: variable product quality and standardization across jurisdictions, potential drug-drug interactions with concurrent antiepileptic medications, and the reality that most epilepsy patients can achieve adequate seizure control with existing FDA-approved agents. The heterogeneity of epilepsy itself means CBD efficacy varies considerably depending on seizure type and underlying etiology, making it unsuitable as first-line therapy for most patients. In practice, CBD may warrant consideration for carefully selected patients with documented drug-resistant epilepsy
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
